Prognosis and Risk Factors in Patients With Asymptomatic Aortic Stenosis and Their Modulation by Atorvastatin (20 mg)

American Journal of Cardiology

Volumn 102, Issue 6, 2008, Pages 743-748

  Dichtl, Wolfgang ^a   Alber, Hannes Franz ^a   Feuchtner, Gudrun Maria ^a   Hintringer, Florian ^a   Reinthaler, Markus ^a   Bartel, Thomas ^a   Süssenbacher, Alois ^a   Grander, Wilhelm ^a   Ulmer, Hanno ^a   Pachinger, Otmar ^a   Müller, Silvana ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATORVASTATIN; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ADULT; AGED; AORTA STENOSIS; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTERY CALCIFICATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART HEMODYNAMICS; HUMAN; LIVER FAILURE; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIVARIATE ANALYSIS; PRESSURE GRADIENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UNIVARIATE ANALYSIS;

AGED; AORTIC VALVE; AORTIC VALVE STENOSIS; C-REACTIVE PROTEIN; CALCINOSIS; CHOLESTEROL; DISEASE PROGRESSION; FEMALE; HEART VALVE PROSTHESIS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; PYRROLES; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 50949124650     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2008.04.060     Document Type: Article

References (16)

1. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
2. Otto C.M., Lind B.K., Kitzman D.W., Gersh B.J., and Siscovick D.S. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 341 (1999) 142-147
3. Otto C.M., Burwash I.G., Legget M.E., Munt B.I., Fujioka M., Healy N.L., Kraft C.D., Miyake-Hull C.Y., and Schwaegler R.G. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic and exercise predictors of outcome. Circulation 95 (1997) 2262-2270
4. Rosenhek R., Klaar U., Schemper M., Scholten C., Heger M., Gabriel H., Binder T., Maurer G., and Baumgartner H. Mild and moderate aortic stenosis. Natural history and risk stratification by echocardiography. Eur Heart J 25 (2004) 199-205
5. Rosenhek R., Binder T., Porenta G., Lang I., Christ G., Schemper M., Maurer G., and Baumgartner H. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 343 (2000) 611-617
6. Pai R.G., Kapoor N., Bansal R.C., and Varadarajan P. Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement. Ann Thorac Surg 82 (2006) 2116-2122
7. Galante A., Pietroiusti A., Vellini M., Piccolo P., Possati G., De Bonis M., Grillo R.L., Fontana C., and Favalli C. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol 38 (2001) 1078-1082
8. Bergler-Klein J., Klaar U., Heger M., Rosenhek R., Mundigler G., Gabriel H., Binder T., Pacher R., Maurer G., and Baumgartner H. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 109 (2004) 2302-2308
9. Novaro G.M., Katz R., Aviles R.J., Gottdiener J.S., Cushman M., Psaty B.M., Otto C.M., and Griffin B.P. Clinical factors, but not C-reactive protein, predict progression of calcified aortic-valve disease. The Cardiovascular Health Study. J Am Coll Cardiol 50 (2007) 1992-1999
10. Cowell S.J., Newby D.E., Prescott R.J., Bloomfield P., Reid J., Northridge D.B., and Boon N.A. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 (2005) 2389-2397
11. Mohler III E.R., Wang H., Medenilla E., and Scott C. Effect of statin treatment on aortic valve and coronary artery calcification. J Heart Valve Dis 16 (2007) 378-386
12. Aronow W.S., Ahn C., Kronzon I., and Goldman M.E. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 88 (2001) 693-695
13. Novaro G.M., Tiong I.Y., Pearce G.L., Lauer M.S., Sprecher D.L., and Griffin B.P. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104 (2001) 2205-2209
14. Bellamy M.F., Pellikka P.A., Klarich K.W., Tajik A.J., and Enriquez-Sarano M. Association of cholesterol level, HMG-CoA reductase inhibitor treatment and progression of aortic stenosis in the community. J Am Coll Cardiol 40 (2002) 1723-1730
15. Rosenhek R., Rader F., Loho N., Gabriel H., Heger M., Klaar U., Schemper M., Binder T., Maurer G., and Baumgartner H. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110 (2004) 1291-1295
16. Moura L.M., Ramos S.F., Zamorano J.L., Barros I.M., Azevedo L.F., Rocha-Goncalves F., and Rajamannan N.M. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49 (2007) 554-561